专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070219274A1 (R)-Chiral Halogenated Substituted Fused Heterocyclic Amino Compounds Useful for Inhibiting Cholesterol Ester Transfer Protein Activity 审中-公开
标题翻译：（R） - 用于抑制胆固醇酯转移蛋白活性的手性卤代取代的稠合杂环氨基化合物
公开(公告)号：US20070219274A1
公开(公告)日：2007-09-20
申请号：US11693161
申请日：2007-03-29
申请人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michelle Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
发明人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michelle Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
IPC分类号： A61K31/135 , C07C211/43
CPC分类号： C07D307/42 , A61K31/138 , A61K31/538 , C07B2200/07 , C07C217/84 , C07C217/86 , C07C217/88 , C07C217/90 , C07C239/20 , C07C323/19 , C07C323/20 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/65 , C07D251/42 , C07D333/20
摘要： The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-1）的抑制剂的取代的芳基和杂芳基（R） - 手性卤代1-取代氨基 - （n + 1） - 阿尔卡醇化合物，化合物，组合物和方法用于治疗动脉粥样硬化和其他冠状动脉疾病。描述了从手性和非手性中间体制备手性取代的烷醇化合物的新型高产率立体选择性方法。

2. 发明申请

US20060229304A1 (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity 失效
公开(公告)号：US20060229304A1
公开(公告)日：2006-10-12
申请号：US11373770
申请日：2006-03-09
申请人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
发明人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
IPC分类号： A61K31/538 , C07D265/36 , A61K31/138
CPC分类号： C07D307/42 , A61K31/138 , A61K31/538 , C07B2200/07 , C07C217/84 , C07C217/86 , C07C217/88 , C07C217/90 , C07C239/20 , C07C323/19 , C07C323/20 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/65 , C07D251/42 , C07D333/20
摘要： The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

3. 发明申请

US20050043294A1 (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity 失效
标题翻译：（R） - 用于抑制胆固醇酯转移蛋白活性的卤代取代稠合杂环氨基化合物
公开(公告)号：US20050043294A1
公开(公告)日：2005-02-24
申请号：US10929013
申请日：2004-08-27
申请人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
发明人： James Sikorski , Richard Durley , Margaret Grapperhaus , Mark Massa , Emily Reinhard , Yvette Fobian , Michael Tollefson , Lijuan Wang , Brian Hickory , Monica Norton , William Vernier , Deborah Mischke , Michele Promo , Ashton Hamme , Dale Spangler , Melvin Rueppel
IPC分类号： C07C217/84 , C07C217/86 , C07C217/88 , C07C217/90 , C07C239/20 , C07C323/19 , C07C323/20 , C07C323/32 , C07D213/65 , C07D251/42 , C07D307/42 , C07D333/20 , A61K31/55 , A61K31/137 , A61K31/47
CPC分类号： C07D307/42 , A61K31/138 , A61K31/538 , C07B2200/07 , C07C217/84 , C07C217/86 , C07C217/88 , C07C217/90 , C07C239/20 , C07C323/19 , C07C323/20 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07D213/65 , C07D251/42 , C07D333/20
摘要： The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-1）的抑制剂的取代的芳基和杂芳基（R） - 手性卤代1-取代氨基 - （n + 1） - 阿尔卡醇化合物，化合物，组合物和方法用于治疗动脉粥样硬化和其他冠状动脉疾病。描述了从手性和非手性中间体制备手性取代的烷醇化合物的新型高产率立体选择性方法。

4. 发明申请

US20050009838A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors 失效
标题翻译：哌啶基和哌嗪基 - 磺酰基甲基异羟肟酸及其作为蛋白酶抑制剂的用途
公开(公告)号：US20050009838A1
公开(公告)日：2005-01-13
申请号：US10618288
申请日：2003-04-25
申请人： Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , David Brown , Jeffery Carroll , Yiyuan Chen , Yvette Fobian , John Freskos , Alan Gasiecki , Margaret Grapperhaus , Robert Heintz , Susan Hockerman , Darren Kassab , Ish Khanna , Stephen Kolodziej , Mark Massa , Joseph McDonald , Brent Mischke , Deborah Mischke , Patrick Mullins , Mark Nagy , Monica Norton , Joseph Rico , Michelle Schmidt , Nathan Stehle , John Talley , William Vernier , Clara Villamil , Lijuan Wang , Thomas Wynn
发明人： Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , David Brown , Jeffery Carroll , Yiyuan Chen , Yvette Fobian , John Freskos , Alan Gasiecki , Margaret Grapperhaus , Robert Heintz , Susan Hockerman , Darren Kassab , Ish Khanna , Stephen Kolodziej , Mark Massa , Joseph McDonald , Brent Mischke , Deborah Mischke , Patrick Mullins , Mark Nagy , Monica Norton , Joseph Rico , Michelle Schmidt , Nathan Stehle , John Talley , William Vernier , Clara Villamil , Lijuan Wang , Thomas Wynn
IPC分类号： C07D295/22 , A61K31/451 , A61K31/453 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/472 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61P1/02 , A61P1/04 , A61P1/14 , A61P1/16 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/08 , A61P13/02 , A61P13/12 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P25/00 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P37/02 , A61P39/00 , A61P41/00 , A61P43/00 , C07D211/66 , C07D211/96 , C07D213/74 , C07D309/08 , C07D335/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D411/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04 , A61K31/445 , C07D211/26
CPC分类号： C07D213/74 , C07D211/66 , C07D211/96 , C07D309/08 , C07D335/02 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D411/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04
摘要： This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula: (wherein A1, A2, Y, E1, E2, E3, and Rx are as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
摘要翻译：本发明一般涉及蛋白酶（也称为“蛋白酶”）抑制剂，尤其涉及哌啶基和哌嗪基 - 磺酰基甲基异羟肟酸，其特别是抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP “）活性和/或蛋白聚糖蛋白聚糖酶活性。这种异羟肟酸通常在结构上对应于下式：（其中A 1，A 2，Y，E 1，E 2，E 3和R x如本说明书），并且还包括这些化合物的盐。本发明还涉及这种异羟肟酸的组合物，用于合成这种异羟肟酸的中间体，制备这种异羟肟酸的方法，以及用于治疗与MMP活性和/或蛋白聚糖蛋白聚糖酶活性相关的病症（特别是病理状态）的方法。

5. 发明申请

US20050101641A1 Aromatic sulfone hydroxamic acids and their use as protease inhibitors 审中-公开
公开(公告)号：US20050101641A1
公开(公告)日：2005-05-12
申请号：US10992483
申请日：2004-11-17
申请人： John Freskos , Yvette Fobian , Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , Jeffery Carroll , Gary DeCrescenzo , Susan Hockerman , Darren Kassab , Steve Kolodziej , Joseph McDonald , Deborah Mischke , Monica Norton , Joseph Rico , John Talley , Clara Villamil , Lijuan Wang
发明人： John Freskos , Yvette Fobian , Thomas Barta , Daniel Becker , Louis Bedell , Terri Boehm , Jeffery Carroll , Gary DeCrescenzo , Susan Hockerman , Darren Kassab , Steve Kolodziej , Joseph McDonald , Deborah Mischke , Monica Norton , Joseph Rico , John Talley , Clara Villamil , Lijuan Wang
IPC分类号： C07D491/048 , A61K31/35 , A61K31/351 , A61K31/357 , A61K31/381 , A61K31/397 , A61K31/4025 , A61K31/404 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/42 , A61K31/423 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/4355 , A61K31/4433 , A61K31/445 , A61K31/453 , A61K31/454 , A61K31/4545 , A61K31/455 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/53 , A61K31/5377 , A61P1/02 , A61P1/04 , A61P1/16 , A61P7/00 , A61P7/02 , A61P7/04 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P25/00 , A61P25/18 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/04 , A61P35/00 , A61P35/04 , A61P37/02 , A61P37/06 , A61P39/00 , A61P43/00 , C07D211/66 , C07D309/08 , C07D309/12 , C07D401/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D491/04 , A61K31/401
CPC分类号： C07D401/12 , A61K31/351 , A61K31/41 , A61K31/453 , A61K31/454 , C04B35/632 , C07D211/66 , C07D309/08 , C07D309/12 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D491/04 , Y02A50/411
摘要： This invention is directed to aromatic sulfone hydroxamic acids (including hydroxamates) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.

6. 发明申请

US20050113451A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors 审中-公开
标题翻译：可用作一氧化氮合酶抑制剂的2-氨基-2-烷基-5-庚烯和庚炔酸衍生物
公开(公告)号：US20050113451A1
公开(公告)日：2005-05-26
申请号：US10978817
申请日：2004-11-01
申请人： Donald Hansen , Ronald Webber , Barnett Pitzele , James Sikorski , Mark Massa , Timothy Hagen , Margaret Grapperhaus , Lijuan Wang , Arija Bergmanis , Steven Kramer , E. Hallinan
发明人： Donald Hansen , Ronald Webber , Barnett Pitzele , James Sikorski , Mark Massa , Timothy Hagen , Margaret Grapperhaus , Lijuan Wang , Arija Bergmanis , Steven Kramer , E. Hallinan
IPC分类号： C07D265/32 , A61K31/198 , A61P1/02 , A61P1/04 , A61P1/16 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/02 , A61P19/08 , A61P21/04 , A61P25/04 , A61P25/06 , A61P25/28 , A61P27/02 , A61P27/06 , A61P29/00 , A61P35/00 , A61P37/00 , A61P43/00 , C07C229/30 , C07C237/16 , C07C257/14 , C07C259/14 , C07C271/22 , C07D271/06 , C07D271/07 , C07D413/06 , C07F7/18 , C07C291/00
CPC分类号： C07D271/07 , C07B2200/07 , C07B2200/09 , C07C229/30 , C07C257/14 , C07C259/14 , C07C271/22 , C07D413/06 , C07F7/1804
摘要： The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.
摘要翻译：本发明涉及2-氨基-2-烷基-5-庚烯酸和庚炔酸衍生物及其在治疗中的用途，特别是其用作一氧化氮合酶抑制剂。

7. 发明申请

US20120284029A1 PHOTO-REALISTIC SYNTHESIS OF IMAGE SEQUENCES WITH LIP MOVEMENTS SYNCHRONIZED WITH SPEECH 有权
标题翻译：具有与语音同步的LIP运动的图像序列的照片 - 现实综合
公开(公告)号：US20120284029A1
公开(公告)日：2012-11-08
申请号：US13098488
申请日：2011-05-02
申请人： Lijuan Wang , Frank Soong
发明人： Lijuan Wang , Frank Soong
IPC分类号： G10L21/00
CPC分类号： G10L21/10 , G10L2021/105
摘要： Audiovisual data of an individual reading a known script is obtained and stored in an audio library and an image library. The audiovisual data is processed to extract feature vectors used to train a statistical model. An input audio feature vector corresponding to desired speech with which a synthesized image sequence will be synchronized is provided. The statistical model is used to generate a trajectory of visual feature vectors that corresponds to the input audio feature vector. These visual feature vectors are used to identify a matching image sequence from the image library. The resulting sequence of images, concatenated from the image library, provides a photorealistic image sequence with lip movements synchronized with the desired speech.
摘要翻译：读取已知脚本的个人的视听数据被获取并存储在音频库和图像库中。处理视听数据以提取用于训练统计模型的特征向量。提供了与合成图像序列将被同步的期望语音相对应的输入音频特征向量。统计模型用于生成对应于输入音频特征向量的视觉特征向量的轨迹。这些视觉特征向量用于识别来自图像库的匹配图像序列。从图像库连接的所得到的图像序列提供了与期望语音同步的唇部运动的照片级逼真图像序列。

8. 发明申请

US20120116761A1 Minimum Converted Trajectory Error (MCTE) Audio-to-Video Engine 有权
标题翻译：最小转换轨迹误差（MCTE）音频到视频引擎
公开(公告)号：US20120116761A1
公开(公告)日：2012-05-10
申请号：US12939528
申请日：2010-11-04
申请人： Lijuan Wang , Frank Kao-Ping Soong
发明人： Lijuan Wang , Frank Kao-Ping Soong
IPC分类号： G10L15/00
CPC分类号： G10L21/06 , G10L21/10 , G10L2021/105
摘要： Embodiments of an audio-to-video engine are disclosed. In operation, the audio-to-video engine generates facial movement (e.g., a virtual talking head) based on an input speech. The audio-to-video engine receives the input speech and recognizes the input speech as a source feature vector. The audio-to-video engine then determines a Maximum A Posterior (MAP) mixture sequence based on the source feature vector. The MAP mixture sequence may be a function of a refined Gaussian Mixture Model (GMM). The audio-to-video engine may then use the MAP to estimate video feature parameters. The video feature parameters are then interpreted as facial movement. The facial movement may be stored as data to a storage module and/or it may be displayed as video to a display device.
摘要翻译：公开了音频到视频引擎的实施例。在操作中，音频到视频引擎基于输入语音产生面部动作（例如，虚拟通话头）。音频到视频引擎接收输入语音并将输入语音识别为源特征向量。音频到视频引擎然后基于源特征向量确定最大后验（MAP）混合序列。 MAP混合序列可以是精细高斯混合模型（GMM）的函数。音频到视频引擎然后可以使用MAP估计视频特征参数。视频功能参数被解释为面部动作。面部运动可以作为数据存储到存储模块和/或其可以作为视频显示到显示装置。

9. 发明申请

US20050148777A1 Benzopyran compounds useful for treating inflammatory conditions 失效
标题翻译：可用于治疗炎性疾病的苯并吡喃化合物
公开(公告)号：US20050148777A1
公开(公告)日：2005-07-07
申请号：US10801429
申请日：2004-03-16
申请人： Jeffery Carter , David Brown , Li Xing , Karl Aston , John Springer , Francis Koszyk , Steven Kramer , Renee Huff , Yi Yu , Bruce Hamper , Subo Laio , Angela Deprow , Theresa Fletcher , E. Hallinan , James Kiefer , David Limburg , Lijuan Wang , Cindy Ludwig , John McCall , John Talley
发明人： Jeffery Carter , David Brown , Li Xing , Karl Aston , John Springer , Francis Koszyk , Steven Kramer , Renee Huff , Yi Yu , Bruce Hamper , Subo Laio , Angela Deprow , Theresa Fletcher , E. Hallinan , James Kiefer , David Limburg , Lijuan Wang , Cindy Ludwig , John McCall , John Talley
IPC分类号： A61K31/352 , A61K31/382 , A61K31/395 , A61K31/47 , A61K31/4709 , A61P29/00 , C07D20060101 , C07D215/38 , C07D215/54 , C07D311/58 , C07D311/64 , C07D311/92 , C07D335/06 , C07D401/02 , C07D405/02 , C07D407/02 , C07D409/02 , C07D493/04
CPC分类号： C07D311/58 , C07D311/64 , C07D405/04 , C07D405/06 , C07D405/12 , C07D407/04 , C07D407/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D417/04 , C07D417/06 , C07D493/04
摘要： The subject invention concerns methods and compounds that have utility in the treatment of a condition associated with cyclooxygenase-2 mediated disorders. Compounds of particular interest are benzopyrans and their analogs defined by formula 1 Wherein Z, X, R1, R 2, R3, and R4 are as described in the specification.
摘要翻译：本发明涉及可用于治疗与环氧合酶-2介导的病症有关的病症的方法和化合物。特别感兴趣的化合物是苯并吡喃及其由式1定义的类似物，其中Z，X，R 1，R 2，R 3和R 4 >如说明书中所述。

10. 发明授权

US06765023B2 Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity 失效
标题翻译：用于抑制胆固醇酯转移蛋白活性的取代的N，N-二取代的反向氨基醇化合物的用途
公开(公告)号：US06765023B2
公开(公告)日：2004-07-20
申请号：US10155921
申请日：2002-05-23
申请人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
发明人： James A. Sikorski , Richard C. Durley , Deborah A. Mischke , Emily J. Reinhard , Yvette M. Fobian , Michael B. Tollefson , Lijuan Wang , Margaret L. Grapperhaus , Brian S. Hickory , Mark A. Massa , Monica B. Norton , William F. Vernier , Barry L. Parnas , Michele A. Promo , Ashton T. Hamme , Dale P. Spangler , Melvin L. Rueppel
IPC分类号： A61K31133
CPC分类号： C07C323/25 , B01D2201/345 , C07B2200/07 , C07C215/08 , C07C215/16 , C07C217/58 , C07C217/84 , C07C217/88 , C07C217/90 , C07C217/92 , C07C219/06 , C07C219/28 , C07C219/34 , C07C225/22 , C07C229/38 , C07C229/52 , C07C229/60 , C07C233/25 , C07C233/43 , C07C233/69 , C07C233/80 , C07C235/20 , C07C235/24 , C07C235/56 , C07C237/30 , C07C237/38 , C07C255/13 , C07C255/21 , C07C255/24 , C07C255/54 , C07C255/58 , C07C271/28 , C07C275/34 , C07C275/40 , C07C311/21 , C07C311/58 , C07C317/32 , C07C317/36 , C07C323/19 , C07C323/20 , C07C323/31 , C07C323/32 , C07C323/37 , C07C323/44 , C07C323/65 , C07C327/30 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2603/18 , C07D207/335 , C07D209/82 , C07D213/38 , C07D213/62 , C07D225/08 , C07D239/26 , C07D239/34 , C07D251/46 , C07D257/04 , C07D263/04 , C07D265/14 , C07D295/088 , C07D295/108 , C07D295/135 , C07D295/192 , C07D307/04 , C07D307/38 , C07D333/20 , C07D333/28 , C07D491/10
摘要： The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted reverse aminoalcohols. A preferred specific N,N-disubstituted reverse aminoalcohols is the compound:
摘要翻译：本发明涉及可用作胆固醇酯转移蛋白（CETP;血浆脂质转移蛋白-I）抑制剂的取代多环芳基和杂芳基叔杂烷基胺化合物以及用于治疗动脉粥样硬化和其它冠状动脉疾病的化合物，组合物和方法。优选的叔杂烷基胺化合物是取代的N，N-二取代的反向氨基醇。优选的具体的N，N-二取代的反向氨基醇是化合物：

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式